Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 133 to 135 of 135 entries
Sorted by: Best Match Show Resources per page
Protein Tyrosine Phosphatases: Mechanisms in Cancer.

International journal of molecular sciences

Sivaganesh V, Sivaganesh V, Scanlon C, Iskander A, Maher S, Lê T, Peethambaran B.
PMID: 34884670
Int J Mol Sci. 2021 Nov 28;22(23). doi: 10.3390/ijms222312865.

Protein tyrosine kinases, especially receptor tyrosine kinases, have dominated the cancer therapeutics sphere as proteins that can be inhibited to selectively target cancer. However, protein tyrosine phosphatases (PTPs) are also an emerging target. Though historically known as negative regulators...

Cite
Sivaganesh V, Sivaganesh V, Scanlon C, et al. Protein Tyrosine Phosphatases: Mechanisms in Cancer. Int J Mol Sci. 2021;22(23)doi: 10.3390/ijms222312865.
Sivaganesh, V., Sivaganesh, V., Scanlon, C., Iskander, A., Maher, S., Lê, T., & Peethambaran, B. (2021). Protein Tyrosine Phosphatases: Mechanisms in Cancer. International journal of molecular sciences, 22(23), . https://doi.org/10.3390/ijms222312865
Sivaganesh, Vignesh, et al. "Protein Tyrosine Phosphatases: Mechanisms in Cancer." International journal of molecular sciences vol. 22,23 (2021). doi: https://doi.org/10.3390/ijms222312865
Sivaganesh V, Sivaganesh V, Scanlon C, Iskander A, Maher S, Lê T, Peethambaran B. Protein Tyrosine Phosphatases: Mechanisms in Cancer. Int J Mol Sci. 2021 Nov 28;22(23). doi: 10.3390/ijms222312865. PMID: 34884670; PMCID: PMC8657787.
Copy Download .nbib Format: NLM
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.

The oncologist

Zalcberg JR, Heinrich MC, George S, Bauer S, Schöffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JY.
PMID: 34313371
Oncologist. 2021 Nov;26(11):e2053-e2060. doi: 10.1002/onco.13917. Epub 2021 Aug 16.

BACKGROUND: Ripretinib 150 mg once daily (QD) is indicated for advanced gastrointestinal stromal tumors (GISTs) as at least fourth-line therapy. In INVICTUS, ripretinib intrapatient dose escalation (IPDE) to 150 mg b.i.d. was allowed after progressive disease (PD) on 150...

Cite
Zalcberg JR, Heinrich MC, George S, et al. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021;26(11):e2053-e2060doi: 10.1002/onco.13917.
Zalcberg, J. R., Heinrich, M. C., George, S., Bauer, S., Schöffski, P., Serrano, C., Gelderblom, H., Jones, R. L., Attia, S., D'Amato, G., Chi, P., Reichardt, P., Somaiah, N., Meade, J., Reichert, V., Shi, K., Sherman, M. L., Ruiz-Soto, R., von Mehren, M., & Blay, J. Y. (2021). Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. The oncologist, 26(11), e2053-e2060. https://doi.org/10.1002/onco.13917
Zalcberg, John R, et al. "Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study." The oncologist vol. 26,11 (2021): e2053-e2060. doi: https://doi.org/10.1002/onco.13917
Zalcberg JR, Heinrich MC, George S, Bauer S, Schöffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JY. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021 Nov;26(11):e2053-e2060. doi: 10.1002/onco.13917. Epub 2021 Aug 16. PMID: 34313371; PMCID: PMC8571742.
Copy Download .nbib Format: NLM
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.

Circulation research

Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ.
PMID: 34110908
Circ Res. 2021 Jun 11;128(12):1973-1987. doi: 10.1161/CIRCRESAHA.121.318259. Epub 2021 Jun 10.

Novel targeted cancer therapies have revolutionized oncology therapies, but these treatments can have cardiovascular complications, which include heterogeneous cardiac, metabolic, and vascular sequelae. Vascular side effects have emerged as important considerations in both cancer patients undergoing active treatment and...

Cite
Fleming MR, Xiao L, Jackson KD, et al. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circ Res. 2021;128(12):1973-1987doi: 10.1161/CIRCRESAHA.121.318259.
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021). Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circulation research, 128(12), 1973-1987. https://doi.org/10.1161/CIRCRESAHA.121.318259
Fleming, Matthew R, et al. "Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors." Circulation research vol. 128,12 (2021): 1973-1987. doi: https://doi.org/10.1161/CIRCRESAHA.121.318259
Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circ Res. 2021 Jun 11;128(12):1973-1987. doi: 10.1161/CIRCRESAHA.121.318259. Epub 2021 Jun 10. PMID: 34110908.
Copy Download .nbib Format: NLM
Showing 133 to 135 of 135 entries